Module

The Changing Face of Antiviral Therapy in Hepatitis B

Source: Hepatitis Annual Update 2006

The Changing Face of Antiviral Therapy in Hepatitis B

Program Director: Emmet B. Keeffe, MD, MACP

Faculty:

Robert P. Perrillo, MD

CME CREDIT INFORMATION

Release Date: 08/01/06

Expiration Date: 07/31/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Review advances with currently licensed antivirals and those in late-stage development
State the findings of recent studies linking long-term disease complications to hepatitis B virus replication
Discuss the implications that long-term antiviral suppression could have on the management of hepatitis B virus

Topics covered include:

Introduction
Peginterferon Treatment for Chronic Hepatitis B
Nucleos(t)ide Analogues: Recent Advances
Combination Therapies for Hepatitis B
Relationship of Long-term Complications to HBV DNA Level: Is a New Treatment Paradigm Indicated?
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.